Medpace Delivers Strong Q3 Performance

Medpace Holdings (NASDAQ: MEDP) soared 17% after reporting better-than-expected Q3 results and raising its full-year outlook, underscoring continued strength in the clinical research services sector.

Earnings Highlights

Q3 Revenue: $659.9 million, up 24% year-over-year
Non-GAAP EPS: $3.86, up from $3.01 a year earlier
Both revenue and earnings exceeded consensus estimates

The company attributed its strong results to robust demand across Phase II–IV clinical programs, especially in oncology and metabolic diseases.

Raised Full-Year 2025 Guidance

Medpace lifted its full-year forecasts:

Revenue: Now expected between $2.48B and $2.53B
(vs. prior guidance of $2.42B–$2.52B)
Non-GAAP EPS: Raised to $14.60–$14.86
(vs. prior range of $13.76–$14.53)

Both targets are above analyst consensus, signaling management confidence in continued contract momentum and operational efficiency.

Strategic Momentum

Medpace continues to benefit from:

Increased outsourcing of drug development by biotech and pharma firms
Strong backlog growth in new clinical trial awards
Expansion in global site capacity and digital trial technologies

The company’s consistent execution has positioned it as one of the most profitable CROs (Contract Research Organizations) in the sector.

Market Reaction

Investors rewarded the beat-and-raise quarter, with MEDP shares jumping 17% in early trading — marking one of the largest single-day gains for the stock this year.